Phase 1 VT3989 Transcription Factor Inhibitor Trial

This multi-center, open-label study evaluates VT3989 given alone or with immunotherapy (nivolumab/ipilimumab) or targeted therapy (osimertinib) in patients with advanced or metastatic mesothelioma and solid tumors resistant to standard treatments. Sponsored by Vivace Therapeutics, Inc, the trial focuses on tumors with molecular profiles such as NF2 mutations and exon 19 deletions.